JUNSHI BIO (688180.SH): Application for clinical trials of injectable JS212 has been accepted.
Junshi Biosciences (688180.SH) has issued an announcement. The company has received approval from the National Medical Products Administration for the issuance of the "Acceptance...".
JUNSHI BIO (688180.SH) announces that the company has received the "Acceptance Notification" issued by the National Medical Products Administration for the clinical trial application of injection JS212 (project code "JS212"). JS212 is a recombinant humanized dual-specific antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), primarily used for the treatment of advanced malignant solid tumors.
Related Articles
US Stock Market Move | Hut8 (HUT.US) continues to rise by over 5%, accumulating a total increase of 37% over the past 3 trading days.
US Stock Market Move | Received a $3.75 million purchase order Unusual Machines (UMAC.US) continued to rise by over 8%
A-share Evening Focus | Precious Metals Bull Market Continues! London Copper Breaks $12,000
US Stock Market Move | Hut8 (HUT.US) continues to rise by over 5%, accumulating a total increase of 37% over the past 3 trading days.
US Stock Market Move | Received a $3.75 million purchase order Unusual Machines (UMAC.US) continued to rise by over 8%
A-share Evening Focus | Precious Metals Bull Market Continues! London Copper Breaks $12,000
RECOMMEND
